News | December 28, 2009

PET Aids Dopamine Cell Transplantation for Parkinson’s Patients

January 4, 2010 - Patients demonstrated significant improvements in motor skills and brain function in a large-scale study conducted to measure the effectiveness of dopamine cell transplantation in Parkinson’s disease patients shows, according to research reported in the January issue of The Journal of Nuclear Medicine (JNM).

In the study, positron emission tomography (PET) played a critical role in assessing graft survival. The results of this study demonstrate that transplanted cells were viable and integrated well with the host brain tissue. Furthermore, these cells produced dopamine that helped support the brain and led to an improvement in motor symptoms. These improvements were sustained over a four-year study period.

"This study provided new insights into the time course of transplantation outcome," said David Eidelberg, M.D., study co-author and director of the Neuroscience Center at the Feinstein Institute for Medical Research in Manhasset, N.Y. "Comprehensive long-term clinical follow-up, together with molecular imaging, allows for a more realistic appraisal of this kind of intervention for Parkinson’s disease." 
Researchers reported long-term clinical and imaging outcomes after transplantation from 33 patients who originally participated in a one-year, double-blind, placebo-controlled trial of embryonic dopaminergic cell implantation for Parkinson’s disease. Clinical improvement in motor ratings, as well as increased brain uptake of 18F-fluorodopa (18F-FDOPA), the radiotracer that is widely used to investigate the function of dopamine grafts, was evident at one, two and four years after the transplantation surgery.
According to the researchers, the findings in the study demonstrate the critical roles played by PET in screening patients for transplantation procedures and in objectively assessing graft survival over the long term.
"This work provides a valuable template for conducting imaging-based trials of cell transplantation for Parkinson’s disease and perhaps other neurodegenerative disorders," said Yilong Ma, Ph.D., lead author of the JNM study and associate investigator at the Feinstein Institute for Medical Research. "It offers guidance in the design of this type of trial, particularly with respect to the use of quantitative imaging as an adjunct to clinical assessments."

While there is presently no cure for Parkinson’s disease, a variety of medications provide dramatic relief from the symptoms. Novel surgical interventions such as cell transplantation and gene therapy are currently being investigated for patients with medically refractory symptoms. 

Co-authors of "Dopamine Cell Implantation in Parkinson’s Disease: Long-Term Clinical and 18F-FDOPA PET Outcomes" include Yilong Ma, Chengke Tang, David Eidelberg, Vijay Dhawan, Thomas Chaly, Center for Neurosciences, The Feinstein Institute for Medical Research, Manhasset, N.Y.; Yilong Ma, Thomas Chaly, David Eidelberg, Vijay Dhawan, Departments of Neurology and Medicine, North Shore University Hospital and New York University School of Medicine, Manhasset, N.Y.; Paul Greene, Stanley Fahn, Department of Neurology, Columbia College of Physicians and Surgeons, New York, N.Y.; Robert Breeze, Department of Neurosurgery, University of Colorado School of Medicine, Denver, Col.; and Curt Freed, Neuroscience Center and Division of Clinical Pharmacology and Toxicology, University of Colorado School of Medicine, Denver, Col.

For more information: jnm.snmjournals.org.

Related Content

RSNA 2017 Celebrates Innovation in Radiology
News | Imaging | January 15, 2018
January 15, 2018 — The Radiological Society of North America’s...

Size comparison between 3-D printed prosthesis implant and a penny.

News | 3-D Printing | January 11, 2018
January 11, 2018 — Researchers using...
RSNA 2017 technical exhibits, expo floor, showing new radiology technology advances.
Feature | RSNA 2017 | January 11, 2018
January 11, 2018 — Here is a list of some of the key clinical study presentations, articles on trends and videos from
The artificial intelligence (AI) smart algorithm onboard the Infervision stroke product calculates the volume of bleed on the basis of multiple brain CT slices.

The AI smart algorithm onboard the Infervision stroke product calculates the volume of bleed on the basis of multiple brain CT slices. The size of the bleed volume indicates the urgency and type of treatment required.

Feature | Artificial Intelligence | January 10, 2018 | Greg Freiherr
Exhibitors at the 2017 Radiological Society of North American (RSNA) meeting rode the...
Upcoming radiology conferences, meetings and events. This photo is from the 2017 RSNA opening session.
News | January 09, 2018
ITN maintains a comprehensive listing of radiology specialty meetings on its website at ...
The new GE Healthcare Air Technology MRI coil design is 60 percent lighter than conventional coils, provides more flexibility and conforms to a patient’s anatomy like a blanket. The technology was unveiled at RSNA 2017 in late November.

The new GE Healthcare Air Technology MRI coil design is 60 percent lighter than conventional coils, provides more flexibility and conforms to a patient’s anatomy like a blanket. The technology was unveiled at RSNA 2017 in late November.

Feature | January 08, 2018 | Dave Fornell
Here is the list of the most popular articles and videos on the Imaging Technology News (ITN) magazine website from t
WEBINAR: Neuroimaging from a Clinical Perspective, sponsored by Philips Healthcare. How to better manage your MRI department.
Webinar | Magnetic Resonance Imaging (MRI) | January 08, 2018
The CME credit webinar "Neuroimaging from a Clinical Perspective," will explain how imaging departments can become mo
Toshiba Medical Systems Changes Name to Canon Medical Systems Corp.
News | Business | January 08, 2018
Canon Inc. and Canon Medical Systems Corp. announced the official corporate name (trade name) change of Canon Group...
Banner Health Extends Partnership With Philips for PerformanceBridge Practice
News | Analytics Software | January 02, 2018
Philips and Arizona-based Banner Health recently announced they have extended their multi-year partnership to include...
About 25 percent of screening patients and 60 percent of diagnostic patients do not have prior mammograms available for comparison at the time of their examinations due to the lack of interoperability or other restrictions preventing clinicians from accessing prior exams.

About 25 percent of screening patients and 60 percent of diagnostic patients do not have prior mammograms available for comparison at the time of their examinations due to the lack of interoperability or other restrictions preventing clinicians from accessing prior exams.

Feature | Breast Imaging | January 02, 2018 | Kathryn Pearson Peyton, M.D.
Sixty million women undergo regular screening mammography in the United States, but even in the digital age, it is di
Overlay Init